Sphingomyelinase-responsive nanomicelles for targeting atherosclerosis.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Atherosclerosis, a major cause of cardiovascular disease, needs improved monitoring and treatment strategies.
• Nanoparticles offer potential for targeted diagnostics and therapeutics in atherosclerotic plaques.
• Limited availability of specific biomarkers for targeting atherosclerosis hinders nanoparticle development.

Purpose of the Study:

• To investigate the use of sphingomyelin-based nanomicelles triggered by sphingomyelinase (SMase) for atherosclerotic plaque targeting.
• To explore SMase as a mechanism for retaining nanoprobes within atherosclerotic lesions.

Main Methods:

• Development of sphingomyelin-based nanomicelles.
• Administration of iron oxide-based nanomicelles into atherosclerotic plaques.
• Assessment of nanomicelle accumulation using fluorescence, MR imaging, and electron microscopy.

Main Results:

• Demonstrated successful accumulation of iron oxide-based nanomicelles within atherosclerotic plaques.
• Confirmed nanomicelle retention in plaques, indicating SMase-triggered localization.
• Visualized nanomicelle distribution via fluorescence, MR imaging, and electron microscopy.

Conclusions:

• Sphingomyelinase (SMase) can serve as a trigger to retain nanoprobes within atherosclerotic plaques.
• This SMase-mediated retention mechanism opens new avenues for targeted nanoparticle-based diagnostics and therapeutics in atherosclerosis.
• The findings support the development of advanced nanoparticle strategies for cardiovascular disease management.